Ophthalmology Times: May 2021

Increased access is key to preventing disease progression in patients.

Physicians are left to determine which treatments can offer patients best outcomes.

Retrospective review highlights the sustained efficacy of combination procedure.

RGX-314 eyed by investigators as a therapeutic option for exudative AMD.

Bi-sign design compensates for aberrations resulting from misalignment.

Use of such procedures increased markedly in analysis of IRIS Registry Data.

UK physician notes a full systemic work-up needed to determine source of infection.

Study results show that aflibercept-treated eyes are protected.

Study results show the device offers an effective long-term option for patients.

Therapeutic choices beneficial for patients may be available in 1 to 3 years.

A word from Chief Medical Editor Peter J. McDonnell, MD.

Check out the latest cartoon!

Short learning curve, significant clinical advantages make this a comfortable addition.

Clues to dangerous etiologies include pain and positive imaging findings.